Nick Deeter, CEO of WishBone Medical, signs the agreement with Hospital for Special Surgery.

WARSAW — WishBone Medical, a new global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants, entered into a license agreement with the global leader in orthopedic surgery, Hospital for Special Surgery, for the development of a novel pediatric total hip. The system will be developed to address treatment of juvenile idiopathic arthritis patients or young patients with congenital dysplastic hip disease.

“We look forward to working with HSS on a Pediatric Total Hip system designed just for kids,” said Nick Deeter, chairman of the board and CEO at WishBone Medical. “HSS is the premier musculoskeletal hospital in the world and their expertise and collaboration will be invaluable to develop this technology.”

“HSS’s clinical leadership, biomechanical engineering and innovation expertise together with Wishbone’s experience developing technologies to serve pediatric patients, position us to improve the quality of life of these young patients who do not have many therapeutic options,” said Louis Shapiro, president and CEO of HSS.

“As an inventor of these technologies, Dr. Mark Figgie, our Chief of the Surgical Arthritis Service at HSS is a leading expert in the field, who along with our biomechanical engineers have a long history in both treating and innovating for this patient population,” Shapiro added.